139 related articles for article (PubMed ID: 32233234)
1. [Efficacy and safety of lycopene in the treatment of benign prostatic hyperplasia with lower urinary tract symptoms].
Li YZ; Liang WN; Zhang GW; Weng ZQ; Zhong Y; Xu S; Shang XJ
Zhonghua Nan Ke Xue; 2019 Nov; 25(11):1001-1004. PubMed ID: 32233234
[TBL] [Abstract][Full Text] [Related]
2. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
Crocerossa F; Cantiello F; Bagalá L; Sicoli F; Carbonara U; Manfredi C; Falagario U; Veccia A; Pandolfo SD; Napolitano L; Ferro M; Di Dio M; Mondaini N; Damiano R
Urol Int; 2023; 107(10-12):924-934. PubMed ID: 37939691
[TBL] [Abstract][Full Text] [Related]
3. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
4. Serenoa repens + selenium + lycopene vs tadalafil 5 mg for the treatment of lower urinary tract symptoms secondary to benign prostatic obstruction: a Phase IV, non-inferiority, open-label, clinical study (SPRITE study).
Morgia G; Vespasiani G; Pareo RM; Voce S; Madonia M; Carini M; Ingrassia A; Terrone C; Gentile M; Carrino M; Giannantoni A; Blefari F; Arnone S; Santelli G; Russo GI;
BJU Int; 2018 Aug; 122(2):317-325. PubMed ID: 29569389
[TBL] [Abstract][Full Text] [Related]
5. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
Singh DV; Mete UK; Mandal AK; Singh SK
J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
[TBL] [Abstract][Full Text] [Related]
6. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms.
Jhang JF; Jiang YH; Kuo HC
Int J Clin Pract; 2013 Dec; 67(12):1327-33. PubMed ID: 24246211
[TBL] [Abstract][Full Text] [Related]
7. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
8. How much improvement is needed for a real difference of lower urinary tract symptoms after long-term combination therapy for benign prostatic hyperplasia.
Jiang YH; Liao CH; Kuo HC
Int J Clin Pract; 2014 Sep; 68(9):1081-6. PubMed ID: 24673775
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Singh I; Tk A; Gupta S
Int J Clin Pract; 2020 Aug; 74(8):e13530. PubMed ID: 32542854
[TBL] [Abstract][Full Text] [Related]
10. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates.
Wang M; Guo L; Duan F; Yuan K; Zhang G; Li K; Yan J; Wang Y; Kang H
BJU Int; 2016 Jan; 117(1):155-64. PubMed ID: 25851432
[TBL] [Abstract][Full Text] [Related]
11. [Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : A short-term clinical observation].
Deng ZX; Ji LX; Zhang YR; Li CD; Cai J; Jiang HH
Zhonghua Nan Ke Xue; 2018 Janurary; 24(1):72-77. PubMed ID: 30157365
[TBL] [Abstract][Full Text] [Related]
12. Serenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial).
Morgia G; Russo GI; Voce S; Palmieri F; Gentile M; Giannantoni A; Blefari F; Carini M; Minervini A; Ginepri A; Salvia G; Vespasiani G; Santelli G; Cimino S; Allegro R; Collura Z; Fragalà E; Arnone S; Pareo RM
Prostate; 2014 Nov; 74(15):1471-80. PubMed ID: 25154739
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
15. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Clinical Outcomes of Prostatic Artery Embolization with 50-μm Plus 100-μm Polyvinyl Alcohol (PVA) Particles versus 100-μm PVA Particles Alone: A Prospective Randomized Trial.
Wang MQ; Zhang JL; Xin HN; Yuan K; Yan J; Wang Y; Zhang GD; Fu JX
J Vasc Interv Radiol; 2018 Dec; 29(12):1694-1702. PubMed ID: 30297313
[TBL] [Abstract][Full Text] [Related]
17. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
Lee JH; Kim Y; Park YW; Lee DG
J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
[TBL] [Abstract][Full Text] [Related]
18. Prostate Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Results From a Prospective FDA-Approved Investigational Device Exemption Study.
Salem R; Hairston J; Hohlastos E; Riaz A; Kallini J; Gabr A; Ali R; Jenkins K; Karp J; Desai K; Thornburg B; Casalino D; Miller F; Hofer M; Hamoui N; Mouli S
Urology; 2018 Oct; 120():205-210. PubMed ID: 30036614
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
20. Effect of preoperative detrusor underactivity on long-term surgical outcomes of photovaporization and holmium laser enucleation in men with benign prostatic hyperplasia: a lesson from 5-year serial follow-up data.
Cho MC; Yoo S; Park J; Cho SY; Son H; Oh SJ; Paick JS
BJU Int; 2019 May; 123(5A):E34-E42. PubMed ID: 30582661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
